Materials and methods for immunosuppressive tumor microenvironment-targeted cancer therapy
AssigneeUniversity of Cincinnati
InventorsXiaoyang Qi, Subrahmanya Duttu Vallabhapurapu
Life of this patent
Estimating the term…
Loading patent…
AssigneeUniversity of Cincinnati
InventorsXiaoyang Qi, Subrahmanya Duttu Vallabhapurapu
Estimating the term…
Many tumors induce and maintain an immunosuppressive tumor microenvironment (TME) that enables tumor to escape host immune system. The present disclosure identifies that cancer cells secrete exosome/microparticle-free, soluble, phosphorylated Hsp70 (pHsp70) (Heat Shock Protein 70 (Hsp70))), which triggers macrophage (M) M2 polarization. It is a further aspect that lipid nanovesicles (NVs) made of dioleoylphosphatidylglycerol (DOPG) and of DOPG complexed with saposin C (SapC) bind to cancer secreted Hsp70, inhibit M differentiation and polarization, and reduce tumor growth. In addition, administration of DOPG-NVs rendered monocytes insensitive to TLR2 (Toll Like Receptor 2) and TLR6 (Toll Like Receptor 6) ligands, suggesting that administration of DOPG-NVs interferes with TLR function.
A method for treating a cancerous or pre-cancerous cell comprising administering to the cell a therapeutically effective amount of lipid nanovesicles, wherein the lipid consists of dioleoylphosphatidylglycerol (DOPG).
A method for treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of lipid nanovesicles, wherein the lipid consists of dioleoylphosphatidylglycerol (DOPG).
A method of treating glioblastoma in a subject in need thereof, the method comprising administering to the subject an effective amount of a lipid nanovesicle complex consisting of dioleoylphosphatidylglycerol (DOPG) complexed with saposin C (SapC).
Dependencies are inferred from the claim text.